Denali Non Currrent Assets Other from 2010 to 2024
| DNLI Stock | USD 17.14 0.33 1.96% |
Non Currrent Assets Other | First Reported 2016-12-31 | Previous Quarter 11.1 M | Current Value 16.5 M | Quarterly Volatility 5.1 M |
Check Denali Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Denali main balance sheet or income statement drivers, such as Depreciation And Amortization of 17.6 M, Interest Expense of 8.6 M or Selling General Administrative of 54.3 M, as well as many exotic indicators such as Price To Sales Ratio of 8.47, Dividend Yield of 0.0 or PTB Ratio of 2.17. Denali financial statements analysis is a perfect complement when working with Denali Therapeutics Valuation or Volatility modules.
Denali | Non Currrent Assets Other |
Latest Denali Therapeutics' Non Currrent Assets Other Growth Pattern
Below is the plot of the Non Currrent Assets Other of Denali Therapeutics over the last few years. It is assets that are not physical or tangible, expected to provide value for more than one year, and not easily converted into cash, such as long-term investments or patents. Denali Therapeutics' Non Currrent Assets Other historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Denali Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Non Currrent Assets Other | 10 Years Trend |
|
Non Currrent Assets Other |
| Timeline |
Denali Non Currrent Assets Other Regression Statistics
| Arithmetic Mean | 4,908,277 | |
| Geometric Mean | 988,402 | |
| Coefficient Of Variation | 130.92 | |
| Mean Deviation | 5,499,569 | |
| Median | 1,441,000 | |
| Standard Deviation | 6,425,766 | |
| Sample Variance | 41.3T | |
| Range | 17.3M | |
| R-Value | 0.86 | |
| Mean Square Error | 11.7T | |
| R-Squared | 0.74 | |
| Significance | 0.000041 | |
| Slope | 1,234,282 | |
| Total Sum of Squares | 578.1T |
Denali Non Currrent Assets Other History
About Denali Therapeutics Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include Denali Therapeutics income statement, its balance sheet, and the statement of cash flows. Denali Therapeutics investors use historical funamental indicators, such as Denali Therapeutics's Non Currrent Assets Other, to determine how well the company is positioned to perform in the future. Although Denali Therapeutics investors may use each financial statement separately, they are all related. The changes in Denali Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Denali Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Denali Therapeutics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Denali Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Non Currrent Assets Other | 16.5 M | 17.4 M |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Denali Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Denali Therapeutics' short interest history, or implied volatility extrapolated from Denali Therapeutics options trading.
Pair Trading with Denali Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Denali Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Denali Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Denali Stock
| 0.76 | BMY | Bristol Myers Squibb Earnings Call This Week | PairCorr |
Moving against Denali Stock
| 0.41 | QLI | Qilian International | PairCorr |
The ability to find closely correlated positions to Denali Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Denali Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Denali Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Denali Therapeutics to buy it.
The correlation of Denali Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Denali Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Denali Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Denali Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of Denali Therapeutics Correlation against competitors. For more detail on how to invest in Denali Stock please use our How to Invest in Denali Therapeutics guide.You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Complementary Tools for Denali Stock analysis
When running Denali Therapeutics' price analysis, check to measure Denali Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Denali Therapeutics is operating at the current time. Most of Denali Therapeutics' value examination focuses on studying past and present price action to predict the probability of Denali Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Denali Therapeutics' price. Additionally, you may evaluate how the addition of Denali Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Global Correlations Find global opportunities by holding instruments from different markets |
Is Denali Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Denali Therapeutics. If investors know Denali will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Denali Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.06) | Revenue Per Share 2.406 | Quarterly Revenue Growth (1.00) | Return On Assets (0.09) | Return On Equity (0.14) |
The market value of Denali Therapeutics is measured differently than its book value, which is the value of Denali that is recorded on the company's balance sheet. Investors also form their own opinion of Denali Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Denali Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Denali Therapeutics' market value can be influenced by many factors that don't directly affect Denali Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Denali Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Denali Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Denali Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.